By Matt Chiappardi ( November 10, 2014, 2:06 PM EST) -- Cancer drug maker Dendreon Corp., which develops and markets Provenge, filed for Chapter 11 protection in Delaware on Monday, looking to either pursue a stand-alone restructuring of its roughly $650 million in debt or a sale if it can fetch more than $275 million for the company....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.